CAR–T – media

Ultrasound tech genetically controls cells to kill cancer new study finds

Researchers say the approach breaks new ground in treating cancer non-invasively and with unprecedented precision.
- Source: Healthcare IT news
- 589
- February 6, 2018
cancer CAR–T immunotherapy Researches
Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer

Celgene agreed on Monday to buy the rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
- Source: Cnbc
- 990
- January 24, 2018
cancer CAR–T Market Views
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, announced the completion of a $49.5 million Series A financing to further build its technology platform and advance its lead programs toward clinical development.
- Source: Businesswire
- 568
- December 8, 2017
CAR–T Market Views Series
Stanford, NCI Researchers Discover New CAR-T Target With Early Study Data

Researchers at Stanford University School of Medicine with the National Cancer Institute (NCI) have identified another cancer-surface molecule, CD22, and begun trials on B-cell acute lymphoblastic leukemia (ALL) patients using an immuno-oncology approach similar to CAR-T. In the Phase I trial, 15 of the 21 patients who had previously relapsed or did not respond to anti-CD19 CAR-T, were treated with an anti-CD22 CAR-T therapy. Ten of the 15 patients had already received treatment for CD19-targeted treatment.
- Source: biospace
- 580
- November 22, 2017
cancer CAR–T immuno-oncology Researches
Novartis Slams Down $3.9B for This French Cancer Biotech

Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9 billion acquisition of French cancer firm Advanced Accelerator Applications.
- Source: Biospace
- 808
- October 31, 2017
CAR–T GEP-NETs Market Views neuroendocrine tumors
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA

Kite, a Gilead Company, announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
- Source: Businesswire
- 688
- October 20, 2017
B-cell lymphoma CAR–T FDA Market Views Yescarta
FDA Okays Another CAR T-Cell Therapy

The FDA has approved a second chimeric antigen receptor (CAR) T-cell therapy for cancer: Kite Pharma's axicabtagene ciloleucel (Yescarta) for the treatment of certain types of refractory large B-cell lymphoma, the agency announced.
- Source: medpagetoday
- 756
- October 19, 2017
cancer CAR–T FDA New Approvals
FDA holds trials of Cellectis’ cell therapy after patient death

US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.
- Source: news.open-medical
- 590
- September 6, 2017
BPDCN CAR–T Clinical Trials Company Insight CRS
Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors

A collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T) (RELATED: Kite begins EU trial of CAR–T therapy) was announced by Takeda Pharmaceutical Company Limited (TSE: 4502) and Noile-Immune Biotech Inc..
- Source: Takeda
- 906
- September 6, 2017
antigen CAR–T Market Views receptor therapy
Kite begins EU trial of CAR–T therapy

Kite Pharma has begun treating the first EU patients with its investigational CAR–T candidate, axicabtagene ciloleucel (axi-cel), in the safety expansion cohort of the ZUMA-1 trial.
- Source: pharmatimes
- 865
- August 10, 2017
CAR–T Clinical Trials Company Insight EU FDA

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.